Correction: Fenofibrate improves renal lipotoxicity through activation of AMPK-PGC-1α in db/db mice (PLoS ONE (2014) 9, 5 (e96147) DOI: 10.1371/journal.pone.0096147);Fenofibrate improves renal lipotoxicity through activation of AMPK-PGC-1α in db/db mice

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Hong, Yu Ah ^a   Lim, Ji Hee ^b   Kim, Min Young ^b   Kim, Tae Woo ^b   Kim, Yaeni ^b   Yang, Keun Suk ^b   Park, Hoon Suk ^b   Choi, Sun Ryoung ^b   Chung, Sungjin ^b   Kim, Hyung Wook ^b   Kim, Hye Won ^b   Choi, Bum Soon ^b   Chang, Yoon Sik ^b   Park, Cheol Whee ^b  

^a Korea University College of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTANE; ACETYL COENZYME A CARBOXYLASE; BINDING PROTEIN; CARBOHYDRATE REGULATORY ELEMENT-BINDING PROTEIN 1; COLLAGEN TYPE 4; COPPER ZINC SUPEROXIDE DISMUTASE; ESTROGEN RELATED RECEPTOR ALPHA; FATTY ACID; FENOFIBRATE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MANGANESE SUPEROXIDE DISMUTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; THREONINE; TRANSCRIPTION FACTOR FKHRL1; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, MOUSE; PPARGC1A PROTEIN, MOUSE; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; KIDNEY HYPERTROPHY; KIDNEY MEDULLA; LIPID STORAGE; LIPOTOXICITY; MALE; MOUSE; NEPHROTOXICITY; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RENAL PROTECTION; SIGNAL TRANSDUCTION; URINE LEVEL; ANIMAL; C57BL MOUSE; DIABETIC NEPHROPATHIES; DRUG EFFECTS; DYSLIPIDEMIAS; KIDNEY; METABOLISM;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; DIABETIC NEPHROPATHIES; DYSLIPIDEMIAS; FENOFIBRATE; FORKHEAD TRANSCRIPTION FACTORS; HYPOLIPIDEMIC AGENTS; KIDNEY; MALE; MICE; MICE, INBRED C57BL; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTORS;

EID: 84900387354     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105921     Document Type: Erratum

References (47)

1. Decleves AE, Sharma K (2010) New pharmacological treatments for improving renal outcomes in diabetes. Nat Rev Nephrol 6: 371-380.
2. Schena FP, Gesualdo L (2005) Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 16 Suppl 1: S30-33. (Pubitemid 41725079)
3. Tan AL, Forbes JM, Cooper ME (2007) AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol 27: 130-143. (Pubitemid 46550311)
4. Murea M, Freedman BI, Parks JS, Antinozzi PA, Elbein SC, et al. (2010) Lipotoxicity in diabetic nephropathy: the potential role of fatty acid oxidation. Clin J Am Soc Nephrol 5: 2373-2379.
5. Moorhead JF, Chan MK, El-Nahas M, Varghese Z (1982) Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2: 1309-1311. (Pubitemid 13240921)
6. Ruan XZ, Moorhead JF, Fernando R, Wheeler DC, Powis SH, et al. (2004) Regulation of lipoprotein trafficking in the kidney: role of inflammatory mediators and transcription factors. Biochem Soc Trans 32: 88-91. (Pubitemid 38283021)
7. Issemann I, Green S (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645-650.
8. Portilla D, Dai G, Peters JM, Gonzalez FJ, Crew MD, et al. (2000) Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure. Am J Physiol Renal Physiol 278: F667-675. (Pubitemid 30215246)
9. Park CW, Kim HW, Ko SH, Chung HW, Lim SW, et al. (2006) Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha. Diabetes 55: 885-893.
10. Park CW, Zhang Y, Zhang X, Wu J, Chen L, et al. (2006) PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 69: 1511-1517.
11. Shin SJ, Lim JH, Chung S, Youn DY, Chung HW, et al. (2009) Peroxisome proliferator-activated receptor-alpha activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats. Hypertens Res 32: 835-845.
12. Goya K, Sumitani S, Xu X, Kitamura T, Yamamoto H, et al. (2004) Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol 24: 658-663. (Pubitemid 38451600)
13. Okayasu T, Tomizawa A, Suzuki K, Manaka K, Hattori Y (2008) PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation. Life Sci 82: 884-891.
14. Schreiber SN, Emter R, Hock MB, Knutti D, Cardenas J, et al. (2004) The estrogen-related receptor alpha (ERRalpha) functions in PPARgamma coactivator 1alpha (PGC-1alpha)-induced mitochondrial biogenesis. Proc Natl Acad Sci U S A 101: 6472-6477. (Pubitemid 38585998)
15. Rangwala SM, Li X, Lindsley L, Wang X, Shaughnessy S, et al. (2007) Estrogen-related receptor alpha is essential for the expression of antioxidant protection genes and mitochondrial function. Biochem Biophys Res Commun 357: 231-236. (Pubitemid 46574520)
16. Proctor G, Jiang T, Iwahashi M, Wang Z, Li J, et al. (2006) Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes 55: 2502-2509. (Pubitemid 44871150)
17. Canto C, Auwerx J (2009) PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 20: 98-105.
18. Buler M, Aatsinki SM, Skoumal R, Komka Z, Toth M, et al. (2012) Energy-sensing factors coactivator peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha) and AMP-activated protein kinase control expression of inflammatory mediators in liver: induction of interleukin 1 receptor antagonist. J Biol Chem 287: 1847-1860.
19. Puigserver P, Wu Z, Park CW, Graves R, Wright M, et al. (1998) A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92: 829-839. (Pubitemid 28155321)
20. Soyal S, Krempler F, Oberkofler H, Patsch W (2006) PGC-1alpha: a potent transcriptional cofactor involved in the pathogenesis of type 2 diabetes. Diabetologia 49: 1477-1488. (Pubitemid 43848083)
21. Moore DD (2012) Nuclear receptors reverse McGarry's vicious cycle to insulin resistance. Cell Metab 15: 615-622.
22. Villena JA, Kralli A (2008) ERRalpha: a metabolic function for the oldest orphan. Trends Endocrinol Metab 19: 269-276.
23. Olmos Y, Valle I, Borniquel S, Tierrez A, Soria E, et al. (2009) Mutual dependence of Foxo3a and PGC-1alpha in the induction of oxidative stress genes. J Biol Chem 284: 14476-14484.
24. Ouali F, Djouadi F, Merlet-Benichou C, Bastin J (1998) Dietary lipids regulate beta-oxidation enzyme gene expression in the developing rat kidney. Am J Physiol 275: F777-784.
25. Hardie DG (2004) The AMP-activated protein kinase pathway - new players upstream and downstream. J Cell Sci 117: 5479-5487.
26. Chen WL, Chen YL, Chiang YM, Wang SG, Lee HM (2012) Fenofibrate lowers lipid accumulation in myotubes by modulating the PPARalpha/AMPK/FoxO1/ATGL pathway. Biochem Pharmacol 84: 522-531.
27. Kim J, Ahn JH, Kim JH, Yu YS, Kim HS, et al. (2007) Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp Eye Res 84: 886-893. (Pubitemid 46590130)
28. Murakami H, Murakami R, Kambe F, Cao X, Takahashi R, et al. (2006) Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC. Biochem Biophys Res Commun 341: 973-978. (Pubitemid 43221761)
29. Kitada M, Takeda A, Nagai T, Ito H, Kanasaki K, et al. (2011) Dietary restriction ameliorates diabetic nephropathy through anti-inflammatory effects and regulation of the autophagy via restoration of Sirt1 in diabetic Wistar fatty (fa/fa) rats: a model of type 2 diabetes. Exp Diabetes Res 2011: 9081-9085.
30. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, et al. (2009) AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458:1056-1060.
31. Vousden Kh, Ryan KM (2009) p53 and metabolism. Nat Rev Cancer 9:691-700.
32. Nakae J, Oki M, Cao Y (2008) The FoxO transcription factors and metabolic regulation. FEBS Lett 582:54-67. (Pubitemid 350297245)
33. Alvarez-Guardia D, Palomer X, Coll T, Davidson MM, Chan TO, et al. (2010) The p65 subunit of NF-kappaB binds to PGC-1alpha, linking inflammation and metabolic disturbances in cardiac cells. Cardiovasc Res 87:449-458.
34. Kim MY, Lim JH, Youn HH, Hong YA, Yang KS, et al. (2013) Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1alpha axis in db/db mice. Diabetologia 56: 204-217.
35. Housley MP, Udeshi ND, Rodgers JT, Shabanowitz J, Puigserver P, et al. (2009) A PGC-1alpha-O-GlcNAc transferase complex regulates FoxO transcription factor activity in response to glucose. J Biol Chem 284: 5148-5157.
36. Rodgers JT, Lerin C, Gerhart-Hines Z, Puigserver P (2008) Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways. FEBS Lett 582: 46-53. (Pubitemid 350297246)
37. Villena JA, Hock MB, Chang WY, Barcas JE, Giguere V, et al. (2007) Orphan nuclear receptor estrogen-related receptor alpha is essential for adaptive thermogenesis. Proc Natl Acad Sci U S A 104: 1418-1423. (Pubitemid 46184019)
38. Schreiber SN, Knutti D, Brogli K, Uhlmann T, Kralli A (2003) The transcriptional coactivator PGC-1 regulates the expression and activity of the orphan nuclear receptor estrogen-related receptor alpha (ERRalpha). J Biol Chem 278: 9013-9018. (Pubitemid 36800379)
39. Mootha VK, Handschin C, Arlow D, Xie X, St Pierre J, et al. (2004) Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle. Proc Natl Acad Sci U S A 101: 6570-6575. (Pubitemid 38586015)
40. Huss JM, Torra IP, Staels B, Giguere V, Kelly DP (2004) Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol Cell Biol 24: 9079-9091. (Pubitemid 39313912)
41. Dentin R, Pegorier JP, Benhamed F, Foufelle F, Ferre P, et al. (2004) Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. J Biol Chem 279: 20314-20326. (Pubitemid 38623477)
42. Ishigaki N, Yamamoto T, Shimizu Y, Kobayashi K, Yatoh S, et al. (2007) Involvement of glomerular SREBP-1c in diabetic nephropathy. Biochem Biophys Res Commun 364: 502-508. (Pubitemid 350026495)
43. Barreyro FJ, Kobayashi S, Bronk SF, Werneburg NW, Malhi H, et al. (2007) Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J Biol Chem 282: 27141-27154. (Pubitemid 47501972)
44. Gross DN, Wan M, Birnbaum MJ (2009) The role of FOXO in the regulation of metabolism. Curr Diab Rep 9: 208-214.
45. Chung HW, Lim JH, Kim MY, Shin SJ, Chung S, et al. (2012) High-fat diet-induced renal cell apoptosis and oxidative stress in spontaneously hypertensive rat are ameliorated by fenofibrate through the PPARalpha-FoxO3a- PGC-1alpha pathway. Nephrol Dial Transplant. 27:2213-2225.
46. Frier BC, Jacobs RL, Wright DC (2011) Interactions between the consumption of a high-fat diet and fasting in the regulation of fatty acid oxidation enzyme gene expression: an evaluation of potential mechanisms. Am J Physiol Regul Integr Comp Physiol 300: R212-221.
47. Jager S, Handschin C, St-Pierre J, Spiegelman BM (2007) AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci U S A 104: 12017-12022. (Pubitemid 47185622)